Published in Hypertension on January 11, 2010
Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2015) 2.03
Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol (2011) 1.03
Salt-dependent inhibition of epithelial Na+ channel-mediated sodium reabsorption in the aldosterone-sensitive distal nephron by bradykinin. Hypertension (2012) 0.90
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair (2011) 0.87
Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem (2011) 0.85
The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens (2012) 0.83
eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol (2012) 0.82
Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors. Cardiovasc Diabetol (2013) 0.82
Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clin Sci (Lond) (2013) 0.81
ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries. Biol Chem (2013) 0.80
Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling. Curr Opin Nephrol Hypertens (2014) 0.80
Knocking out angiotensin II in the heart. Curr Hypertens Rep (2011) 0.80
Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J Biol Chem (2013) 0.79
Metallopeptidase inhibition potentiates bradykinin-induced hyperalgesia. Pain (2011) 0.79
Rhinorrhea, cough and fatigue in patients taking sitagliptin. Allergy Asthma Clin Immunol (2010) 0.78
Downregulation of kinin B1 receptor function by B2 receptor heterodimerization and signaling. Cell Signal (2014) 0.77
Carboxypeptidase M augments kinin B1 receptor signaling by conformational crosstalk and enhances endothelial nitric oxide output. Biol Chem (2013) 0.77
Role of Mas Receptor Antagonist A799 in Renal Blood Flow Response to Ang 1-7 after Bradykinin Administration in Ovariectomized Estradiol-Treated Rats. Adv Pharmacol Sci (2015) 0.76
Effects of a novel bradykinin B1 receptor antagonist and angiotensin II receptor blockade on experimental myocardial infarction in rats. PLoS One (2012) 0.76
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk. Am J Cardiovasc Drugs (2016) 0.75
Effects of a novel ACE inhibitor, 3-(3-thienyl)-l-alanyl-ornithyl-proline, on endothelial vasodilation and hepatotoxicity in l-NAME-induced hypertensive rats. Drug Des Devel Ther (2016) 0.75
Angiotensin-converting enzyme inhibitors reduce oxidative stress intensity in hyperglicemic conditions in rats independently from bradykinin receptor inhibitors. Croat Med J (2016) 0.75
Angiotensin-(1-7) Selectively Induces Relaxation and Modulates Endothelium-Dependent Dilation in Mesenteric Arteries of Salt-Fed Rats. J Vasc Res (2016) 0.75
Functional Local Renin-Angiotensin System in Human and Rat Periodontal Tissue. PLoS One (2015) 0.75
First Report of Eurycoma longifolia Jack Root Extract Causing Relaxation of Aortic Rings in Rats. Biomed Res Int (2016) 0.75
Hemodynamics and vasoactive substance levels during renal congestion that occurs in the anhepatic phase of liver transplantation. World J Gastroenterol (2015) 0.75
Potentiation of Paclitaxel-Induced Pain Syndrome in Mice by Angiotensin I Converting Enzyme Inhibition and Involvement of Kinins. Mol Neurobiol (2016) 0.75
ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL. J Mol Biol (1965) 46.35
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 8.11
Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev (1992) 4.56
The preparation and function of the hypertensin-converting enzyme. J Exp Med (1956) 3.32
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev (2003) 2.93
Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature (2003) 2.78
A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta (1970) 2.48
Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther (1971) 2.19
Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci (2007) 2.13
An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol (1962) 2.08
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01
Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry (1970) 1.86
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest (1997) 1.83
Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res (1999) 1.75
Second kininase in human blood plasma. Nature (1967) 1.52
Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem (1978) 1.51
Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem (1993) 1.45
Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension (2005) 1.42
Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry (1983) 1.37
The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost (2007) 1.35
A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal "protective protein". J Biol Chem (1990) 1.33
Human mast cell carboxypeptidase. Purification and characterization. J Clin Invest (1989) 1.33
An enzyme in microsomal fraction of kidney that inactivates bradykinin. Life Sci (1967) 1.32
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med (2009) 1.27
Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation (2005) 1.24
Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A (2002) 1.19
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension (2008) 1.14
Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol (2000) 1.14
Angiotensin I converting enzyme of the lung. Circ Res (1972) 1.12
Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol (2006) 1.12
Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension (2005) 1.12
Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity. J Mol Biol (2004) 1.09
Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes (2009) 1.09
Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol (2004) 1.09
Dynamic receptor-dependent activation of inducible nitric-oxide synthase by ERK-mediated phosphorylation of Ser745. J Biol Chem (2007) 1.07
Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator. Int Immunopharmacol (2007) 1.05
Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors. J Biol Chem (2000) 1.05
Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J (2009) 1.02
Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem (2002) 1.02
Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension (2008) 1.02
Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension (2002) 1.00
Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol (2008) 1.00
Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv (2009) 0.99
Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol (2002) 0.98
Hydrolysis of opioid hexapeptides by carboxypeptidase N. Presence of carboxypeptidase in cell membranes. Biochem Pharmacol (1984) 0.98
Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists. J Biol Chem (2008) 0.97
Protease-activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J Neurochem (2008) 0.96
Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol (2003) 0.95
Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme. FEBS Lett (2003) 0.95
Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension (2008) 0.95
Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J (2006) 0.93
The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res (2004) 0.92
Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension (1999) 0.92
Naturally occurring active N-domain of human angiotensin I-converting enzyme. Proc Natl Acad Sci U S A (1994) 0.91
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol (2008) 0.90
Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol (2005) 0.89
Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol (2009) 0.88
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation (2004) 0.88
Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol (1994) 0.88
Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther (2000) 0.88
L-NAME-resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: effect of ACE inhibition. Br J Pharmacol (2000) 0.87
Structure of testis ACE glycosylation mutants and evidence for conserved domain movement. Biochemistry (2006) 0.87
Effects of the N-terminal sequence of ACE on the properties of its C-domain. Hypertension (2000) 0.87
Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J Pharmacol Exp Ther (2006) 0.87
Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol (2004) 0.86
ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res (1993) 0.86
[Phe8 psi(CH2-NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase II. Eur J Pharmacol (1988) 0.85
Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries. Hypertension (2007) 0.85
Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol (2002) 0.85
ACE activity is modulated by kinin B2 receptor. Hypertension (2008) 0.84
New fACEs to the renin-angiotensin system. Physiology (Bethesda) (2005) 0.84
Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J Pharmacol Exp Ther (2005) 0.84
Purification of human urinary prokallikrein. Identification of the site of activation by the metalloproteinase thermolysin. Biochem J (1985) 0.84
Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J Mol Biol (2006) 0.83
Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Hypertension (2005) 0.83
Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. Am J Cardiol (1997) 0.83
Single-domain angiotensin I converting enzyme (kininase II): characterization and properties. J Pharmacol Exp Ther (1996) 0.82
Potentiation of bradykinin actions by analogues of the bradykinin potentiating nonapeptide BPP9alpha. Peptides (2005) 0.82
Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography of binding. Mol Pharmacol (2008) 0.81
Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation (1999) 0.81
Soluble dextran complexes of kallikrein. Bradykinin and enzyme inhibitors. Biochem Pharmacol (1978) 0.80
Kinins, receptors, kininases and inhibitors--where did they lead us? Biol Chem (2001) 0.79
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model. Biol Chem (2008) 0.79
Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am J Physiol Heart Circ Physiol (2006) 0.79
Novel mechanism of action of ACE and its inhibitors. Am J Physiol Heart Circ Physiol (2005) 0.79
Carboxypeptidase M in brain and peripheral nerves. J Neurochem (1992) 0.78
Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum. Peptides (2000) 0.76
The kinin system: suggestions to broaden some prevailing concepts. Int Immunopharmacol (2002) 0.76
Novel mechanism of endothelial nitric oxide synthase activation mediated by caveolae internalization in endothelial cells. Circ Res (2006) 1.92
Caveolin-1 regulates store-operated Ca2+ influx by binding of its scaffolding domain to transient receptor potential channel-1 in endothelial cells. Mol Pharmacol (2006) 1.92
Novel mechanisms of G protein-dependent regulation of endothelial nitric-oxide synthase. Mol Pharmacol (2005) 1.48
A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Biol Chem (2006) 1.38
ICAM-1-activated Src and eNOS signaling increase endothelial cell surface PECAM-1 adhesivity and neutrophil transmigration. Blood (2012) 1.17
Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One (2009) 1.16
Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Mol Biol Cell (2012) 1.16
Augmented inducible nitric oxide synthase expression and increased NO production reduce sepsis-induced lung injury and mortality in myeloperoxidase-null mice. Am J Physiol Lung Cell Mol Physiol (2008) 1.14
Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol (2004) 1.09
Crystal structure of human carboxypeptidase M, a membrane-bound enzyme that regulates peptide hormone activity. J Mol Biol (2004) 1.09
Dynamic receptor-dependent activation of inducible nitric-oxide synthase by ERK-mediated phosphorylation of Ser745. J Biol Chem (2007) 1.07
Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem (2002) 1.02
Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension (2002) 1.00
Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient b1 signaling from B2 agonists. J Biol Chem (2008) 0.97
Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol (2003) 0.95
A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase. J Cell Mol Med (2011) 0.93
Human ACE and bradykinin B2 receptors form a complex at the plasma membrane. FASEB J (2006) 0.93
Signaling-mediated functional activation of inducible nitric-oxide synthase and its role in stimulating platelet activation. J Biol Chem (2008) 0.92
Aminopeptidase N reduces basolateral Na+ -K+ -ATPase in proximal tubule cells. Am J Physiol Renal Physiol (2007) 0.89
Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol (2005) 0.89
Activation of bradykinin B1 receptor by ACE inhibitors. Int Immunopharmacol (2002) 0.89
Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium. J Biol Chem (2012) 0.87
Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol (2002) 0.85
Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem (2011) 0.85
Beta-arrestin 2 is required for B1 receptor-dependent post-translational activation of inducible nitric oxide synthase. FASEB J (2010) 0.84
Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J Pharmacol Exp Ther (2005) 0.84
Carboxypeptidase-mediated enhancement of nitric oxide production in rat lungs and microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol (2004) 0.83
Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Hypertension (2005) 0.83
Crystal structure of the human carboxypeptidase N (kininase I) catalytic domain. J Mol Biol (2006) 0.83
Positive cooperativity between the thrombin and bradykinin B2 receptors enhances arachidonic acid release. Am J Physiol Heart Circ Physiol (2005) 0.83
Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor. Hypertension (2002) 0.83
Kallikreins when activating bradykinin B2 receptor induce its redistribution on plasma membrane. Int Immunopharmacol (2002) 0.82
Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process. Am J Physiol Heart Circ Physiol (2009) 0.81
Effect of mutation of two critical glutamic acid residues on the activity and stability of human carboxypeptidase M and characterization of its signal for glycosylphosphatidylinositol anchoring. Biochem J (2003) 0.81
The ectodomain shedding of angiotensin-converting enzyme is independent of its localisation in lipid rafts. J Cell Sci (2003) 0.81
Proliferation of regulatory mechanisms for eNOS: an emerging role for the cytoskeleton. Am J Physiol Lung Cell Mol Physiol (2002) 0.79
Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J Biol Chem (2013) 0.79
Structural characterization of the human carboxypeptidase D gene and its promoter. Int Immunopharmacol (2002) 0.77
Carboxypeptidase M augments kinin B1 receptor signaling by conformational crosstalk and enhances endothelial nitric oxide output. Biol Chem (2013) 0.77
Selective destruction of mouse islet beta cells by human T lymphocytes in a newly-established humanized type 1 diabetic model. Biochem Biophys Res Commun (2010) 0.77
Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N. Biochem J (2005) 0.76
Characterization of dual agonists for kinin B1 and B2 receptors and their biased activation of B2 receptors. Cell Signal (2012) 0.76